MX2022014631A - Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih. - Google Patents

Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih.

Info

Publication number
MX2022014631A
MX2022014631A MX2022014631A MX2022014631A MX2022014631A MX 2022014631 A MX2022014631 A MX 2022014631A MX 2022014631 A MX2022014631 A MX 2022014631A MX 2022014631 A MX2022014631 A MX 2022014631A MX 2022014631 A MX2022014631 A MX 2022014631A
Authority
MX
Mexico
Prior art keywords
trispecific
binding proteins
prevention
treatment
hiv infection
Prior art date
Application number
MX2022014631A
Other languages
English (en)
Inventor
Christian Beil
Christian Lange
Ercole Rao
Ronnie Wei
Huawei Qiu
Jochen Kruip
Tongqing Zhou
Jochen Beninga
Ling Xu
Mark Connors
Jinghe Huang
Amarendra Pegu
Mangaiarkarasi Asokan
Zhi-Yong Yang
Gary J Nabel
Wulf Dirk Leuschner
John R Mascola
Richard A Koup
Nicole A Doria-Rose
Peter D Kwong
Young Do Kwon
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2022014631A publication Critical patent/MX2022014631A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente memoria se proporcionan que comprenden proteínas de unión triespecíficas y/o trivalentes que comprenden cuatro cadenas polipeptídicas que forman tres sitios de unión a antígeno que se unen específicamente a una o más proteínas blanco del VIH o uno o más receptores de células T, en donde un primer par de polipéptidos que forman la proteína de unión posee dominios variables duales que tienen una orientación cruzada y en donde un segundo par de polipéptidos que forman la proteína de unión posee un solo dominio variable. También se proporcionan en la presente memoria métodos para preparar proteínas de unión triespecíficas y/o trivalentes y usos de tales proteínas de unión para el tratamiento y/o la prevención de VIH/SIDA.
MX2022014631A 2015-10-25 2018-04-24 Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih. MX2022014631A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562246113P 2015-10-25 2015-10-25
EP16305211 2016-02-24
US201662322029P 2016-04-13 2016-04-13
US201662331169P 2016-05-03 2016-05-03

Publications (1)

Publication Number Publication Date
MX2022014631A true MX2022014631A (es) 2023-01-11

Family

ID=55588187

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005048A MX2018005048A (es) 2015-10-25 2016-10-24 Proteinas de union triespecificas y/o trivalantes para la prevencion o el tratamiento de la infeccion por vih.
MX2022014631A MX2022014631A (es) 2015-10-25 2018-04-24 Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018005048A MX2018005048A (es) 2015-10-25 2016-10-24 Proteinas de union triespecificas y/o trivalantes para la prevencion o el tratamiento de la infeccion por vih.

Country Status (30)

Country Link
US (4) US20190054182A1 (es)
EP (2) EP3819310A1 (es)
JP (3) JP7169190B2 (es)
KR (1) KR102687212B1 (es)
CN (4) CN116789841A (es)
AR (1) AR106466A1 (es)
AU (2) AU2016347058B2 (es)
BR (1) BR112018008011A2 (es)
CA (1) CA3002664A1 (es)
CL (1) CL2018001065A1 (es)
CO (1) CO2018005337A2 (es)
CR (1) CR20180288A (es)
DO (1) DOP2018000102A (es)
EA (1) EA201891028A1 (es)
ES (1) ES2894304T3 (es)
HR (1) HRP20211528T1 (es)
HU (1) HUE056608T2 (es)
IL (2) IL301140A (es)
MA (1) MA42641A1 (es)
MX (2) MX2018005048A (es)
MY (1) MY192278A (es)
PE (1) PE20181167A1 (es)
PH (1) PH12018500873A1 (es)
PL (1) PL3365366T3 (es)
RS (1) RS62437B1 (es)
SG (1) SG11201803324VA (es)
SI (1) SI3365366T1 (es)
TW (3) TW202442675A (es)
UY (1) UY36965A (es)
WO (1) WO2017074878A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
CN106459186B (zh) * 2014-02-28 2021-02-02 美国卫生和人力服务部 针对hiv-1 v1v2 env区域的广谱中和性单克隆抗体
MX2018005048A (es) 2015-10-25 2018-09-06 Sanofi Sa Proteinas de union triespecificas y/o trivalantes para la prevencion o el tratamiento de la infeccion por vih.
AU2016349392B2 (en) * 2015-11-03 2023-07-13 The Trustees Of Columbia University In The City Of New York Neutralizing antibodies to HIV-1 gp41 and their use
BR112018070998A2 (pt) * 2016-04-13 2019-02-26 Sanofi proteínas de ligação triespecíficas e/ou trivalentes
SI3443006T1 (sl) * 2016-04-13 2024-01-31 Sanofi Trispecifični in/ali trivalentni vezni proteini
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CA3053774A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
WO2018183294A1 (en) * 2017-03-27 2018-10-04 David Weiner Dna antibody constructs for use against hiv
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
CN120058938A (zh) 2017-10-10 2025-05-30 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
WO2019123262A1 (en) * 2017-12-18 2019-06-27 VIIV Healthcare UK (No.5) Limited Antigen binding polypeptides
TWI745643B (zh) * 2017-12-21 2021-11-11 紐約市哥倫比亞大學理事會 雙專一性hiv-1-中和性抗體
WO2019140320A1 (en) 2018-01-12 2019-07-18 Genzyme Corporation Methods for the quantitation of polypeptides
US11845788B2 (en) 2018-05-22 2023-12-19 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (HIV)
MX2021004147A (es) * 2018-10-09 2021-09-08 Sanofi Sa Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.
US12459989B2 (en) * 2018-11-21 2025-11-04 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (HIV)
CN113950484B (zh) * 2019-04-09 2025-07-29 赛诺菲 三特异性结合蛋白、其方法和用途
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
EP4048690A1 (en) 2019-10-25 2022-08-31 Sanofi Methods for analyzing chain mispairing in multispecific binding proteins
WO2021203103A2 (en) * 2020-04-03 2021-10-07 Somasekar Seshagiri Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
MX2023002194A (es) * 2020-08-25 2023-03-03 Gilead Sciences Inc Moleculas multiespecificas de union a antigenos dirigidas al vih y metodos de uso.
US20230235092A1 (en) * 2021-09-29 2023-07-27 Modex Therapeutics Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
TW202325744A (zh) * 2021-09-29 2023-07-01 美商莫德斯醫療公司 用於ｈｉｖ之抗原結合多肽、抗原結合多肽複合物及其使用方法
CN118591388A (zh) * 2021-09-29 2024-09-03 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
WO2025109206A1 (en) 2023-11-22 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025108551A1 (en) 2023-11-23 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025238419A1 (en) 2024-05-17 2025-11-20 Sanofi Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumors

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2058199T3 (es) 1987-09-23 1994-11-01 Bristol Myers Squibb Co Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
CA2433877C (en) 2001-01-17 2014-11-18 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
EP2480572B1 (en) 2009-09-25 2019-01-30 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 and their use
EP3613774A1 (en) 2010-06-09 2020-02-26 Genmab A/S Antibodies against human cd38
JP2014502262A (ja) 2010-11-12 2014-01-30 ザ ロックフェラー ユニバーシティ Ｈｉｖ治療用の融合タンパク質
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
AU2012255266B2 (en) * 2011-05-17 2017-05-25 California Institute Of Technology Human immunodeficiency virus neutralizing antibodies and methods of use thereof
RU2624046C2 (ru) 2011-11-07 2017-06-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз Gp41-нейтрализующие антитела и их применение
EP2776061B1 (en) * 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2900696A1 (en) * 2012-09-25 2015-08-05 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
US9951106B2 (en) 2012-12-04 2018-04-24 University Of Maryland, Baltimore Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
BR112015013700A8 (pt) 2012-12-13 2020-02-18 Inovio Pharmaceuticals Inc composição, sequência nucleotídica, anticorpo sintético, e, uso da composição
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
UA119320C2 (uk) 2013-02-26 2019-06-10 Рош Глікарт Аг Активуюча т-клітини біспецифічна антигензв'язувальна молекула
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
WO2014144299A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFα
WO2015017755A1 (en) 2013-08-02 2015-02-05 The Regents Of The University Of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
EP3066133A1 (en) 2013-11-04 2016-09-14 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
KR102497443B1 (ko) 2014-03-28 2023-02-08 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
CN106687584B (zh) 2014-09-04 2021-08-13 干细胞技术公司 用于t细胞或nk细胞活化和扩增的可溶性抗体复合物
MY191964A (en) 2015-01-23 2022-07-21 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
MX392170B (es) 2015-05-20 2025-03-21 Quantum Si Inc Método para determinar la secuencia de un acido nucleico usando luminiscencia resuelta por tiempo.
WO2016196740A1 (en) 2015-06-02 2016-12-08 The Rockefeller University Tri-specific antibodies for hiv therapy
WO2017053556A1 (en) 2015-09-22 2017-03-30 The Trustees Of The University Of Pennsylvania Method of redirecting t cells to treat hiv infection
MX2018005048A (es) 2015-10-25 2018-09-06 Sanofi Sa Proteinas de union triespecificas y/o trivalantes para la prevencion o el tratamiento de la infeccion por vih.
CN105837688B (zh) 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
MA44077A (fr) 2015-12-15 2021-05-05 Gilead Sciences Inc Anticorps neutralisants le virus de l'immunodéficience humaine
BR112018070998A2 (pt) 2016-04-13 2019-02-26 Sanofi proteínas de ligação triespecíficas e/ou trivalentes
SI3443006T1 (sl) 2016-04-13 2024-01-31 Sanofi Trispecifični in/ali trivalentni vezni proteini
US12234479B2 (en) 2016-12-30 2025-02-25 Cytocares (Shanghai) Inc. Bifunctional molecule and use thereof
CA3053774A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
WO2018183294A1 (en) 2017-03-27 2018-10-04 David Weiner Dna antibody constructs for use against hiv
CN120058938A (zh) 2017-10-10 2025-05-30 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
MX2021004147A (es) 2018-10-09 2021-09-08 Sanofi Sa Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
PH12018500873A1 (en) 2018-11-12
JP7328267B2 (ja) 2023-08-16
CO2018005337A2 (es) 2018-07-10
NZ742825A (en) 2024-04-26
EP3365366A1 (en) 2018-08-29
MA42641A1 (fr) 2019-03-29
KR20180063336A (ko) 2018-06-11
US20220226495A1 (en) 2022-07-21
US11779651B2 (en) 2023-10-10
HUE056608T2 (hu) 2022-02-28
AU2016347058A1 (en) 2018-06-14
CN116789841A (zh) 2023-09-22
SI3365366T1 (sl) 2022-02-28
CN109311966A (zh) 2019-02-05
JP2021072847A (ja) 2021-05-13
IL258822B1 (en) 2023-04-01
DOP2018000102A (es) 2018-11-30
WO2017074878A8 (en) 2018-05-24
CR20180288A (es) 2018-09-11
CN109311966B (zh) 2023-03-10
EA201891028A1 (ru) 2019-02-28
AU2024200395A1 (en) 2024-04-11
US20250312475A1 (en) 2025-10-09
MY192278A (en) 2022-08-16
UY36965A (es) 2017-05-31
KR102687212B1 (ko) 2024-07-19
MX2018005048A (es) 2018-09-06
IL258822A (en) 2018-06-28
JP7724814B2 (ja) 2025-08-18
EP3819310A1 (en) 2021-05-12
TW202442675A (zh) 2024-11-01
SG11201803324VA (en) 2018-05-30
EP3365366B1 (en) 2021-07-14
HK1253385A1 (zh) 2019-06-14
TW201730210A (zh) 2017-09-01
IL258822B2 (en) 2023-08-01
TWI750139B (zh) 2021-12-21
US20190054182A1 (en) 2019-02-21
JP2023085476A (ja) 2023-06-20
PE20181167A1 (es) 2018-07-19
AU2016347058B2 (en) 2023-11-09
ES2894304T3 (es) 2022-02-14
AR106466A1 (es) 2018-01-17
CL2018001065A1 (es) 2018-11-23
WO2017074878A1 (en) 2017-05-04
JP2018537966A (ja) 2018-12-27
NZ781602A (en) 2025-07-25
TW202219064A (zh) 2022-05-16
PL3365366T3 (pl) 2022-01-31
CA3002664A1 (en) 2017-05-04
US11129905B2 (en) 2021-09-28
JP7169190B2 (ja) 2022-11-10
RS62437B1 (sr) 2021-11-30
CN116675776A (zh) 2023-09-01
HRP20211528T1 (hr) 2021-12-24
CN117069855A (zh) 2023-11-17
US20200054765A1 (en) 2020-02-20
BR112018008011A2 (en) 2018-10-30
IL301140A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
MX2022014631A (es) Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih.
CO2018012107A2 (es) Proteínas de unión triespecíficas y/o trivalentes
PE20170767A1 (es) Diacuerpos enlazados covalentemente que tienen inmunoreactividad con pd-1 y lag-3, y metodos de uso de los mismos
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
WO2015197598A3 (en) Multispecific antigen binding proteins
BR112018012707A2 (pt) inibidores da interação de menin-mll
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
WO2016207273A3 (en) Multispecific antigen binding proteins
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
MX2017005977A (es) Anticuerpos biespecificos y metodos de uso en oftalmologia.
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
CO2021014988A2 (es) Proteínas de unión trispecificas y/o trivalentes utilizando el formato de dominio cruzado sobre dual variable (codv) para el tratamiento de la infección por vih
CO2017011583A2 (es) Polipéptidos dirigidos a la fusión de vih
MX2023004804A (es) Proteinas de union triespecificas y/o trivalentes.
EA201892085A1 (ru) Новые белки, полученные из альфа-1-микроглобулина, и их применение
ECSP18039758A (es) Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih
AR118602A1 (es) Proteínas de unión triespecíficas y/o trivalentes para el tratamiento de la infección por vih
EA201790790A1 (ru) Антитела человека против vegfr-2/kdr
ECSP18084491A (es) Proteínas de unión triespecíficas y/o trivalentes
EA202191078A2 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv